Neurology · Nashville area, TN
Neurology studies in Nashville area, TN
40 recruiting studies have a site in the Nashville area. This page includes nearby cities such as Franklin, Brentwood, Murfreesboro, Hermitage.
40 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Daniel Claassen
- Location
- Nashville, TN
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Knoxville, TN + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
Pridopidine Phase 3 Study in Huntington's Disease
Prilenia
- Location
- Nashville, TN + 8 other US sites
- Eligibility basics
- Ages 23–65
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Rapport Therapeutics Inc.
- Location
- Nashville, TN + 12 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Nashville, TN + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Cordova, TN + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Nashville, TN + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Nashville, TN + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Memphis, TN + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Xenon Pharmaceuticals Inc.
- Location
- Nashville, TN + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals
- Location
- Nashville, TN + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Nashville, TN + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Nashville, TN + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Cordova, TN + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Memphis, TN + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Nashville, TN + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Nashville, TN + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Study of EVO756 in Adults With Migraine
Evommune, Inc.
- Location
- Franklin, TN + 32 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Nashville, TN + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Chattanooga, TN + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
Eli Lilly and Company
- Location
- Nashville, TN + 2 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
NewAmsterdam Pharma
- Location
- Nashville, TN
- Eligibility basics
- Ages 55–85
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Nashville, TN + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Memphis, TN + 39 other US sites
- Eligibility basics
- Ages 21–70
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.